Terms: = Kidney tumors AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
92 results:
1. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
2. Systematic Multiomic Analysis of
Kang JY; Yang J; Lee H; Park S; Gil M; Kim KE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203530
[TBL] [Abstract] [Full Text] [Related]
3. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract] [Full Text] [Related]
4. Knockdown of ADAM8 inhibits the proliferation, migration, invasion, and tumorigenesis of renal clear cell carcinoma cells to enhance the immunotherapy efficacy.
Qu H; Mao M; Wang K; Mu Z; Hu B
Transl Res; 2024 Apr; 266():32-48. PubMed ID: 37992987
[TBL] [Abstract] [Full Text] [Related]
5. A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Qin YY; Yang Y; Ren YH; Gao F; Wang MJ; Li G; Liu YX; Fan L
Medicine (Baltimore); 2023 Nov; 102(45):e35829. PubMed ID: 37960824
[TBL] [Abstract] [Full Text] [Related]
6. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract] [Full Text] [Related]
7. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
[TBL] [Abstract] [Full Text] [Related]
8. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
[TBL] [Abstract] [Full Text] [Related]
9. Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology.
Zhong W; Chen H; Yang J; Huang C; Lin Y; Huang J
BMC Med Genomics; 2023 Oct; 16(1):265. PubMed ID: 37885006
[TBL] [Abstract] [Full Text] [Related]
10. Potential value of mitochondrial regulatory pathways in the clinical application of clear cell renal cell carcinoma: a machine learning-based study.
Qi X; Ge Y; Yang A; Liu Y; Wang Q; Wu G
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17015-17026. PubMed ID: 37749329
[TBL] [Abstract] [Full Text] [Related]
11. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
Tai R; Leng J; Li W; Wu Y; Yang J
BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
[TBL] [Abstract] [Full Text] [Related]
12. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
[TBL] [Abstract] [Full Text] [Related]
13. A novel prognostic signature of chemokines for survival and immune infiltration in kidney renal clear cell carcinoma.
Weng J; Huang Z; Li Q; Huang Y; Chen S
Int J Med Sci; 2023; 20(8):1046-1059. PubMed ID: 37484803
[No Abstract] [Full Text] [Related]
14. A risk signature of ubiquitin-specific protease family predict the prognosis and therapy of kidney cancer patients.
Wang R; Liu Y; Li J; Zhao Y; An R; Ma Z
BMC Nephrol; 2023 May; 24(1):153. PubMed ID: 37259026
[TBL] [Abstract] [Full Text] [Related]
15. Identification of immune cell infiltration profiles in renal cell carcinoma and their clinical significance.
Wang L; Song L
Medicine (Baltimore); 2023 May; 102(19):e33732. PubMed ID: 37171354
[TBL] [Abstract] [Full Text] [Related]
16. Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis.
Wang J; Zhao S; Sun J; Wang X; Guan M; Yin J; Tang B
Sci Rep; 2023 Mar; 13(1):4060. PubMed ID: 36906605
[TBL] [Abstract] [Full Text] [Related]
17. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
[TBL] [Abstract] [Full Text] [Related]
18. Construction of a prognostic prediction model for renal clear cell carcinoma combining clinical traits.
Weng Y; Ning P
Sci Rep; 2023 Feb; 13(1):3358. PubMed ID: 36849551
[TBL] [Abstract] [Full Text] [Related]
19. Activated ctla-4-independent immunosuppression of Treg cells disturbs ctla-4 blockade-mediated antitumor immunity.
Watanabe T; Ishino T; Ueda Y; Nagasaki J; Sadahira T; Dansako H; Araki M; Togashi Y
Cancer Sci; 2023 May; 114(5):1859-1870. PubMed ID: 36762794
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma.
Inceman M; Toyran T; Bayazit Y; Izol V; Erdogan S
Pol J Pathol; 2022; 73(3):181-190. PubMed ID: 36734432
[TBL] [Abstract] [Full Text] [Related]
[Next]
